Reset filter
Trefwoorden
Neoplasms, Brain, Benign ×
Meer tonen Trefwoorden
Inhoudsopgave
  1. 1. Klinische studie
  2. 2. Routinedocumentatie
  3. 3. Register-/kohortstudies
  4. 4. Kwaliteitswaarborging
  5. 5. Datastandaard
  6. 6. Patiëntenvragenlijst
  7. 7. Medisch vakgebied
Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

135 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Recurring cancer children (ADVL0212 NCT00053963) - Reporting Period Worksheet cancer (NCT00053963)

- 22-03-15 - 1 Formulier, 5 Itemgroepen, 58 Data-elementen, 1 Taal
Itemgroepen: Header, Patient characteristics, Concomitant Medication, Patient status, Adverse event
ADVL0212: Reporting Period Worksheet FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia NCT00053963 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B1EC15B1-1989-311F-E034-0003BA12F5E7

Eligibility Brain Cancer NCT01065805

- 20-08-19 - 1 Formulier, 2 Itemgroepen, 13 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01065805

dbGaP phs000725 Rare Cancer Tumors Project - pht003882.v2.p1

- 06-01-23 - 9 Formulieren, 1 Itemgroep, 5 Data-elementen, 1 Taal
Itemgroep: pht003882
Principal Investigator: David A. Wheeler, PhD, Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA MeSH: Neoplasms,Brain Neoplasms,Germinoma,Neoplasms, Germ Cell and Embryonal,Endodermal Sinus Tumor,Teratoma,Carcinoma, Embryonal,Choriocarcinoma,Polycythemia Vera,Craniopharyngioma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000725 A large proportion of common cancers affecting patients around the world have been selected for comprehensive cancer genome studies. Further efforts will be needed to tackle the remaining tumor types, including the rare forms of cancers. Although rare, these cancers tend to be more aggressive and fast growing with an early recurrence following initial chemotherapy and poor prognosis. Besides, patients diagnosed with rare cancers may have difficulty finding a physician knowledgeable in treating their type of cancer. While sample collection is a major challenge, the integrated genomic analyses would identify novel causative genes in these rare cancers, shed new light on the biology of the rare cancers, as well as guide novel targeted cancer therapies. Through efficient collaboration, the Human Genome Sequencing Center (HGSC) at Baylor College of Medicine (BCM) has collected/is expected to collect 20 different types of rare cancers, 15-30 cases each. Whole-exome sequencing and high-resolution SNP array analysis were/will be performed for all cases and whole-genome sequencing was designed for a selected subset of the cases. *The Rare Cancer Tumors Cohort is utilized in the following dbGaP sub-studies.* To view genotypes, other molecular data, and derived variables collected in this sub-study, please click on the following sub-study below or in the "Sub-studies" section of this top-level study page phs000725 Rare Cancer Tumors Cohort.- phs000754 Intracranial Germ Cell Tumors - phs000861 Craniopharyngioma Tumors - phs000859 Sezary Syndrome Genomic Analysis

pht003885.v2.p1

1 Itemgroep 3 Data-elementen

pht003886.v2.p1

1 Itemgroep 5 Data-elementen

pht004475.v2.p1

1 Itemgroep 4 Data-elementen

pht004476.v2.p1

1 Itemgroep 6 Data-elementen

pht004585.v2.p1

1 Itemgroep 5 Data-elementen

Eligibility

1 Itemgroep 1 Data-element

HIV Cancer Sunitinib NCT00890747 AMC-061 - Response Evaluation Form (R61)

- 24-06-17 - 1 Formulier, 7 Itemgroepen, 35 Data-elementen, 1 Taal
Itemgroepen: Header Module, Complete Response, Morphologic Complete Remission, Complete Response, Unconfirmed, Complete Response with Incomplete Bone Marrow Recovery, PR, Progressive Disease
AMC-061 Response Evaluation Form (R61) Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy https://clinicaltrials.gov/ct2/show/NCT00890747

Sunitinib in HIV with Cancer NCT00890747 AMC-061 - HIV Viral Load Form (F40)

- 20-06-17 - 1 Formulier, 2 Itemgroepen, 9 Data-elementen, 1 Taal
Itemgroepen: Header Module, HIV Viral Load
AMC-061 HIV Viral Load Form (F40) Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy https://clinicaltrials.gov/ct2/show/NCT00890747

Sunitinib in HIV with Cancer NCT00890747 AMC-061 - Off Study Summary Form (F50)

- 20-06-17 - 1 Formulier, 1 Itemgroep, 4 Data-elementen, 1 Taal
Itemgroep: Off-Study Summary
AMC-061 Off Study Summary Form (F50) Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy https://clinicaltrials.gov/ct2/show/NCT00890747

HIV Cancer Sunitinib NCT00890747 AMC-061 - Pharmacokinetics Form (P61)

- 12-06-17 - 1 Formulier, 2 Itemgroepen, 5 Data-elementen, 1 Taal
Itemgroepen: Header Module, Pharmacodynamics
AMC-061 Pharmacokinetics Form (P61) Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy https://clinicaltrials.gov/ct2/show/NCT00890747

HIV Cancer Sunitinib NCT00890747 AMC-061 - Protocol Deviation Form (DEV)

- 12-06-17 - 1 Formulier, 2 Itemgroepen, 10 Data-elementen, 1 Taal
Itemgroepen: Header Module, Protocol Deviation
AMC-061 Protocol Deviation Form (DEV) Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy https://clinicaltrials.gov/ct2/show/NCT00890747

HIV Cancer Sunitinib NCT00890747 AMC-061 - Missed Visit Form (F35)

- 12-06-17 - 1 Formulier, 2 Itemgroepen, 6 Data-elementen, 1 Taal
Itemgroepen: Header Module, Missed Visit Information
AMC-061 Missed Visit Form (F35) Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy https://clinicaltrials.gov/ct2/show/NCT00890747

HIV with Cancer Baseline AMC-061 NCT00890747 - Baseline Evaluation Form HIV with Cancer NCT00890747

- 20-05-15 - 1 Formulier, 4 Itemgroepen, 19 Data-elementen, 1 Taal
Itemgroepen: Header Module, SOLID TUMOR/LYMPHOMA ASSESSMENT, KAPOSI'S SARCOMA ASSESSMENT, HEMATOLOGIC MALIGNANCY ASSESSMENT
AMC-061 Baseline Evaluation Form (B61) Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy NCT00890747 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=715BD918-9168-2975-E040-BB89AD434610

dbGaP phs000942 Use of WGS for Diagnosis and Discovery in the Cancer Genetics Clinic - Eligibility

- 27-11-24 - 5 Formulieren, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: IG.elig
Principal Investigator: Theodora S. Ross, MD, PhD, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA, and Department of Cancer Genetics, UT Southwestern Medical Center, Dallas, TX, USA MeSH: Neoplasms,Breast Neoplasms,Ovarian Neoplasms,Peritoneal Neoplasms,Skin Neoplasms,Esophageal Neoplasms,Thyroid Neoplasms,Urinary Bladder Neoplasms,Endometrial Neoplasms,Fallopian Tube Neoplasms,Melanoma,Testicular Neoplasms,Bile Duct Neoplasms,Lung Neoplasms,Colonic Neoplasms,Adrenocortical Carcinoma,Carcinoma, Renal Cell,Colonic Polyps,Adenomatous Polyposis Coli,Lymphoma, Large B-Cell, Diffuse,Pheochromocytoma,Paraganglioma,Leiomyoma,Hemangioblastoma,Hyperparathyroidism,Pancreatic Neoplasms,Vulvar Neoplasms,Brain Neoplasms,Liver Neoplasms,Kidney Neoplasms,Prostatic Neoplasms,Glioblastoma,Oncocytoma, renal https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000942 Despite the potential of whole-genome sequencing (WGS) to improve patient diagnosis and care, the empirical value of WGS in the cancer genetics clinic is unknown. We performed WGS on members of two cohorts of cancer genetics patients: those with BRCA1/2 mutations (n = 176) and those without (n = 82). Initial analysis of potentially pathogenic variants (PPVs, defined as nonsynonymous variants with allele frequency 1% in ESP6500) in 163 clinically-relevant genes suggested that WGS will provide useful clinical results. This is despite the fact that a majority of PPVs were novel missense variants likely to be classified as variants of unknown significance (VUS). Furthermore, previously reported pathogenic missense variants did not always associate with their predicted diseases in our patients. This suggests that the clinical use of WGS will require large-scale efforts to consolidate WGS and patient data to improve accuracy of interpretation of rare variants. While loss-of-function (LoF) variants represented only a small fraction of PPVs, WGS identified additional cancer risk LoF PPVs in patients with known BRCA1/2 mutations and led to cancer risk diagnoses in 21% of non-BRCA cancer genetics patients after expanding our analysis to 3209 ClinVar genes. These data illustrate how WGS can be used to improve our ability to discover patients' cancer genetic risks. "Reprinted from doi:10.1016/j.ebiom.2014.12.003, with permission from EBioMedicine."

pht004834.v1.p1

1 Itemgroep 5 Data-elementen

pht004835.v1.p1

1 Itemgroep 5 Data-elementen

pht004836.v1.p1

1 Itemgroep 16 Data-elementen

pht004837.v1.p1

1 Itemgroep 5 Data-elementen

Toxicity - Brain Cancer - Adverse Event Form - 2263172v3.0 - Brain Cancer - Adverse Event Form

- 09-01-15 - 1 Formulier, 4 Itemgroepen, 23 Data-elementen, 1 Taal
Itemgroepen: CRF Header, Brain: Form Administration, Brain: Adverse Events, Comments
Brain Cancer - Adverse Event Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DE93FBC6-0592-249A-E034-0003BA12F5E7

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial